Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

REGENERON PHARMACEUTICALS, INC. Director's Dealing 2021

Dec 14, 2021

29977_dirs_2021-12-14_7c455769-1427-439a-b5fe-a916b1686a2a.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS, INC. (REGN)
CIK: 0000872589
Period of Report: 2021-12-11

Reporting Person: MURPHY ANDREW J (EVP Research)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-12-11 Common Stock F 697 $664.34 Disposed 58470 Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 4269 Indirect